Glutaminase C-IN-1 (Compound 968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts.
性状
Solid
IC50 & Target[1][2]
Glutaminase C
体外研究(In Vitro)
Glutaminase C-IN-1 (Compound 968) (10 μM; 14 d) inhibits cellular transformation in NIH 3T3 cells.
Glutaminase C-IN-1 (10 μM; 6 d) blocks the signaling activity of a specific target of Dbl.
Glutaminase C-IN-1 blocks the transforming activity of human breast cancer cells.
Glutaminase C-IN-1 (10 μM) blocks glutaminolysis in transformed cells.
Glutaminase C-IN-1 preferentially binds to the monomeric state of Glutaminase C.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay
Cell Line:
MDA-MB231 cells, SKBR3 cells, and NIH 3T3 cells
Concentration:
10 μM
Incubation Time:
5 h
Result:
Inhibited cell growth.
体内研究(In Vivo)
Glutaminase C-IN-1 (Compound 968) (200 μg/mouse; i.p.; daily for 12 days) reduces tumor volume in mice.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
SCID mice with P493 B lymphoma cells
Dosage:
200 μg/mouse
Administration:
Intraperitoneal injection, daily for 12 days
Result:
Caused a ~50% reduction in the size of the tumors.